FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Biotech entrepreneur turns talents to venture fund

The Wall Street Journal offers an in-depth look at Michael Jaharis, a noted biotech entrepreneur who recently sold Kos Pharmaceuticals to Abbott for $4.2 billion. Jaharis has launched Vatera Capital, wagering he can still pick a hot prospect. He's already invested in Aveo's fourth round and now he's looking at "dozens" of other plays to put his money to work. He should be well funded: Jaharis owned more than half of Kos when it was sold.

- read the profile from the Wall Street Journal (sub. req.)

Related Articles:
Abbott to buy Kos for $3.7B. Report
Billionaire doubles VC funds. Report
Biotech pioneer bets a billion on Alzheimer's program. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Abbott Labs   Kos Parmaceuticals   Alzheimer's   Billionaire   Pioneer   Biotech Venture Capital   Entrepreneur   AVEO Pharmaceuticals